Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals Expects $56M IPR&D Charge for Q3 2024
Summary
Regeneron Pharmaceuticals, Inc. expects to report an acquired in-process research and development (IPR&D) charge of approximately $56 million for Q3 2024, negatively impacting both GAAP and non-GAAP net income per diluted share by approximately $0.43. This charge relates to development milestone and up-front payments in connection with collaboration and licensing agreements.
Profitelligence Alerts
Get alerts for REGN
Be first to know when Regeneron Pharmaceuticals, Inc. files with the SEC.
Filing Categories
Advertisement
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.
Official SEC Documents
Advertisement